New drug approved_Alecitinib
USFDA recently approved Alecitinib, an antineoplastic agent.
|
Drug
name:
|
Alectinib
|
|
Innovator:
|
Hoffman-LA Roche
|
|
Brand
name:
|
Alecensa
|
|
Chemical
structure:
|
9-ethyl-6,
6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5 H-benzo[b]carbazole-3-carbonitrile
hydrochloride
|
|
Indications:
|
Alecensa is indicated for the treatment
of patients with anaplastic lymphoma kinase (ALK) positive, metastatic non
small cell lung cancer (NSCLC) who have progressed on or are intolerant to
crizotinib.
|
|
Dosage
form:
|
Capsule; oral
|
|
Strengths:
|
150mg
|
Comments
Post a Comment